Get notified when LBRX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Material Weakness (new) — The company discloses material weaknesses in internal control over financial reporting, which could lead to inaccurate financial reporting and loss of investor confidence.
- Single Product Candidate (new) — The company's business is substantially dependent on the successful development and commercialization of LB-102, which may never occur.
- Clinical Trial Safety Data (new) — Phase 2 trial data includes a death in the placebo group and serious adverse events in treatment arms, raising safety concerns for LB-102.
LB Pharmaceuticals' $327.8M IPO prices at $15/share; net proceeds $302.3M
Filed August 11, 2026 · ~1 min read
Key Changes
-
high
LB Pharmaceuticals priced its IPO at $15.00 per share, selling 21,850,000 shares for gross proceeds of $327.8M and net proceeds of $302.3M.
The Offering verify on EDGAR → -
high
The company reported a GAAP net loss of $70.7M for the six months ended June 30, 2026, up from $10.2M in the prior-year period.
Risk Factors verify on EDGAR → -
high
LB Pharmaceuticals has identified material weaknesses in its internal control over financial reporting.
Controls and Procedures verify on EDGAR →
1 more material change behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (P 10-Q) is open in full — no account needed.
Partner
Trade LBRX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 1, 2026 · How we verify